Tizanidine Tablet
Product Images NDC 60505-0252

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 60505-0252). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-1.jpg (Figure 1)

Line graph showing mean tizanidine concentration over time in hours after dosing, comparing 4 mg tablets and capsules under fasted and fed conditions. The y-axis represents plasma tizanidine concentration (ng/mL), and the x-axis represents hours from dosing, up to 24 hours.*

FDA Label Image

Figure-2.jpg (Figure 2)

A line graph showing the mean change in muscle tone over time measured by the Ashworth Score after a single dose of tizanidine. The chart compares placebo, 8 mg tizanidine, and 16 mg tizanidine, illustrating changes from baseline over 6 hours post-dose with 95% confidence intervals.*

FDA Label Image

Figure-3.jpg (Figure 3)

A line graph depicting mean change in muscle tone measured by the Ashworth Scale over seven weeks following dosing. The graph compares tizanidine (mean dose 28.8 mg) with placebo at study weeks 3, 7, and the endpoint, showing improvements in muscle tone with tizanidine indicated by a negative Ashworth score, alongside 95% confidence intervals.*

FDA Label Image

Chemical-structure (Tizanidine Imtb 01)

Chemical structure of tizanidine hydrochloride, showing its molecular arrangement including chlorine and nitrogen atoms in a heterocyclic framework.*

FDA Label Image

Tizanidine-label-2mg.jpg (Tizanidine Label 2mg)

Label for Tizanidine Tablets, USP 2 mg by Apotex Corp. The package contains 150 tablets for oral use. The label includes storage instructions, dosage caution, and warnings about interchangeability with tizanidine or Zanaflex capsules. The NDC is 60505-0251-3. Manufactured by Apotex Inc., Toronto, Ontario, and labeled for Apotex Corp. in Weston, Florida.*

FDA Label Image

Tizanidine-label-4mg-150s.jpg (Tizanidine Label 4mg 150s)

Label for Tizanidine Tablets, USP 4 mg oral tablets, supplied by Apotex Corp. The label states 150 tablets per container, with instructions for storage between 20° to 25°C. It includes a warning that these tablets are not interchangeable with tizanidine or Zanaflex capsules. The label also provides manufacturer information and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.